Chemours (CC) Tops Q1 EPS by 8c; Raises Outlook

Chemours (NYSE: CC) reported Q1 EPS of $0.71, $0.08 better than the analyst estimate of $0.63. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.4 billion.

GUIDANCE:

• Chemours sees FY2021 EPS of $2.84-$3.56, versus the consensus of $2.87.
• Adjusted EBITDA* between $1.10 and $1.25 billion, up $100 million at the midpoint vs. prior outlook
• Free Cash Flow* now expected to be greater than $450 million, up $100 million vs. prior outlook

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge